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ABSTRACT OF DISSERTATION 
 
 
 
 
 
INHIBITION OF CHOLESTEROL SYNTHESIS BY POLICOSANOL  
  
 
 Cholesterol is an essential component of the cell, but excessive blood levels 
are a major risk factor for the development of atherosclerotic plaques that can 
lead to heart disease and stroke, the foremost cause of premature death in 
Western societies.  Policosanol, a mixture of very long chain alcohols derived 
from sugarcane, has gained considerable attention among the public as safe 
and effective means to reduce blood cholesterol levels, a belief based on some 
early clinical studies.  My research investigates one possible mechanism by 
which policosanol might decrease blood cholesterol levels: the inhibition of 
cholesterol synthesis in the liver.  Previous studies with cultured hepatoma cells 
have indicated that policosanol suppresses HMG-CoA reductase activity, the 
regulatory step in cholesterol synthesis, by activation of AMP-kinase, which then 
inactivates HMG-CoA reductase by phosphorylation.  My studies have 
confirmed this activation of AMP-kinase both in hepatoma cells and in whole 
animals after intragastric administration of policosanol.  The present studies 
were also undertaken to identify the upstream signaling mechanism by which 
policosanol activates AMP-kinase.  Treatment of rat hepatoma cells with 
policosanol increased the amount of phosphorylated CaMKK, which can directly 
activate AMP-kinase, but had only a small effect on LKB1, the principal activator 
of AMP-kinase.  Intragastric administration to mice similarly activated CaMKK, 
but not LKB1, in the liver.  To determine if metabolism of policosanol was 
 necessary for activation of AMP-kinase, siRNA-mediated suppression of fatty 
aldehyde dehydrogenase, fatty acyl CoA synthase-4, or β-ketothiolase in 
hepatoma cells prevented the phosphorylation of AMP-kinase and HMG-CoA 
reductase by policosanol, indicating that metabolism of these very long chain 
alcohols to fatty acids and subsequent peroxisomal β-oxidation is necessary for 
the suppression of cholesterol synthesis.  As the principal product of fatty acid 
-oxidation is acetyl-CoA, further studies demonstrated that addition of acetate 
to cells similarly activated AMP-kinase and inactivated HMG-CoA reductase.  
This finding argues that the activation of AMP-kinase by policosanol results from 
the generation of excess acetyl-CoA via peroxisomal metabolism.  Finally, 
although the intestine is a significant source of circulating cholesterol, 
policosanol was unable to activate AMP-kinase in the small intestine.  These 
findings open new perspectives for the control of cholesterol synthesis by 
activators of AMP-kinase. 
 
KEYWORDS: Cholesterol, AMP kinase, HMG-CoA reductase, Hepatoma cells,  
             Policosanol. 
 
 
 
 
 
                                   
 
 
 
                                    
                                     
                                   Subhashis Banerjee 
                 Student’s Signature                                                    
 
  May. 21, 2010 
 Date  
 
 
 
 
  
 
 
 
 
 
 
 
INHIBITION OF CHOLESTEROL SYNTHESIS BY POLICOSANOL   
 
 
 
 
By 
Subhashis Banerjee 
 
 
 
 
 
 
 
 
 
 
 
 
Dr. Todd D Porter      
 Director of Dissertation 
 
Dr. David Orren           
  Director of Graduate Study 
 
May. 21, 2010             
              
 
 
 
 
 
 
 
 
 
 
 
  
 
 
RULES FOR THE USE OF DISSERTATION 
 
Unpublished dissertations submitted for the Doctor’s degree and deposited in 
the University of Kentucky Library are as a rule open for inspection, but are to be 
used only with due regard to the rights of the authors. Bibliographical references 
may be noted, but quotations or summaries of parts may be published only with 
permission of the author, and with the usual scholarly acknowledgements. 
 
Extensive copying or publication of the dissertation in whole or in part also 
requires the consent of the Dean of the Graduate School of the University of 
Kentucky. 
 
A library that borrows this dissertation for use by its patrons is expected to 
secure the signature of each user. 
 
Name                                                        Date 
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
  
 
 
 
 
 
 
 
 
 
 
DISSERTATION 
 
 
 
 
 
 
 
 
 
Subhashis Banerjee  
 
 
 
 
 
 
 
 
 
The Graduate School 
 
University of Kentucky 
 
2010 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
INHIBITION OF CHOLESTEROL SYNTHESIS BY POLICOSANOL   
  
 
 
 
 
 
                 ________________________________ 
 
DISSERTATION 
________________________________ 
 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy in the 
College of Pharmacy 
at the University of Kentucky 
 
By 
Subhashis Banerjee  
 
Lexington, Kentucky 
 
Director: Dr. Todd D Porter, Associate Professor of Pharmaceutical Sciences 
 
Lexington, Kentucky 
 
2010 
 
 
Copyright © Subhashis Banerjee 2010 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
                               Dedicated 
                      To the Almighty who endowed me, 
To my parents and my sister who encouraged me, 
To my supervisor who enabled me. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
ACKNOWLEDGEMENTS 
 
 It gives me great pleasure to acknowledge all those people who have made 
my days as a research student so meaningful and enjoyable.  The list is long 
and it is difficult to do justice to everyone, but this being part of the thesis that is 
read most often, I shall try to come up with as complete a list as possible. 
 I am short of words to express my gratitude to my research supervisor, Dr Todd 
Porter.  I would like to thank him for introducing me to the fascinating world of 
Toxicology and Pharmacology, for providing lots of independence at work and 
never failing to help me out whenever I was stuck with a problem.  I would like 
to thank him for all the valuable input I have got from him during my stay here.  
It’s his vision and continuous encouragement that I remained focused and 
completed my work within three years. 
 I am extremely thankful to my committee members Prof. Gary Gairola, Prof. 
Geza Bruckner and Dr Charles Loftin for providing me valuable suggestions 
whenever approached.  I also extend my thanks to Dr. Eric Smart for being my 
external examiner. 
 Thanks are due to Prof. Mary Vore, Chair of The Department of Toxicology for 
all her advice.  I also extend my sincere gratitude to Prof. Howard P. Glauert, 
with whom I had worked with during the first three years of my graduation. 
 I have met many people in The Departments of Toxicology and Pharmaceutical 
Sciences who have made my stay here extremely joyous.  Special thanks to Dr. 
Elzbieta Stolarczyk, Dr. Sarbani Ghoshal and Enerlyn Lozada for all their help 
and advice.  I would also like to acknowledge my ex lab mate Dr Dev Karan 
Singh whose preliminary work on policosanol I have continued in this research 
work. 
 I am extremely grateful to Ms. Joyce Welch, Colleen Haney and Lida Carter 
from the Graduate Center for Toxicology.  Throughout my graduate study, they 
had been of great help to me. 
 I’ld have never reached this stage of my career without the efforts and the 
blessings showered on me by all my teachers from the very childhood.  I 
iv 
 
express my sincere gratitude to them for teaching me to love the subject Biology. 
 Last but not the least; I don’t have words to express my love and gratitude for 
my parents, Dr. Debashis Banerjee and Dr. Sushma Banerjee.  My parents left 
no stone unturned to provide me with the best and it is their sacrifice, blessings 
and hard work that have helped me to witness this day in my life.  This is also 
an opportunity for me to thank my sister, Soumyaa Banerjee for all her love and 
encouragement. 
 I also take this opportunity to thank Dr. Anthony B D’Souza and Barbara 
D’Souza for their selfless love and constant encouragement through all the ups 
and downs in my life here in USA. 
 My highest regards to the Almighty for making all these people and events 
happen in this life of mine.  I close with sincere prayers and wishes for all. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 v 
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS……………………………………………………..……….iii 
 
LIST OF FIGURES………………………………………………………………........viii 
 
CHAPTER ONE:  BACKGROUND 
Cholesterol and its importance................................................................... 1 
Use of natural products to lower cholesterol .............................................. 4 
Policosanol lowers blood cholesterol ......................................................... 7 
Policosanol decreases cholesterol synthesis ............................................. 8 
Composition and metabolism of policosanol .............................................. 9 
Regulation of HMG-CoA reductase activity .............................................. 12 
Very long chain fatty alcohol metabolism ................................................. 16 
Inhibition of cholesterol synthesis in hepatoma cells by policosanol ........ 20 
 
CHAPTER TWO:  EXPERIMENTAL RATIONALE 
Experimental rationale ............................................................................. 24 
Specific aims ............................................................................................ 25 
 
CHAPTER THREE:  MATERIALS AND METHODS 
Chemicals ................................................................................................ 26 
Policosanol. ............................................................................................. 26 
Cell culture ............................................................................................... 27 
Animals .................................................................................................... 27 
Gel electrophoresis and immunoblotting .................................................. 28 
Immunoprecipitation ................................................................................. 29 
Plasmid preparation ................................................................................. 29 
Transfections ........................................................................................... 32 
RT-PCR ................................................................................................... 32 
 
 vi 
CHAPTER FOUR:  RESULTS  
Phosphorylation of AMP-kinase and HMG-CoA reductase after  
policosanol treatment ............................................................................... 35 
Activation of pathways upstream of AMP-kinase by policosanol .............. 44 
Activation of AMP-kinase by policosanol requires peroxisomal  
Metabolism .............................................................................................. 47 
Activation of AMP-kinase by policosanol results from the  
generation of excess acetyl-CoA via peroxisomal metabolism ................ 53 
Policosanol does not activate AMP-kinase in the small intestine ............. 58 
 
CHAPTER FIVE:  SUMMARY OF RESULTS 
Summary of  ............................................................................................ 60 
 
CHAPTER SIX:  DISCUSSION 
Discussion ............................................................................................... 63 
 
REFERENCES ................................................................................................... 68 
 
VITA .................................................................................................................... 84 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
LIST OF TABLES 
 
Table 3.1: shRNA plasmid sequences used for silencing genes ......................... 31 
Table 3.2: Gene specific primers used in real-time PCR .................................... 34 
 
 viii 
LIST OF FIGURES 
 
FIGURE 1.1 Cholesterol transport in the body ..................................................... 3 
FIGURE 1.2 Gas chromatogram of policosanol...................................................11 
FIGURE 1.3 Known physiological target proteins and pathways 
regulated by the AMPK system........................................................................... 15 
FIGURE 1.4 Fatty alcohol cycle and peroxisomal β-oxidation ............................ 17 
FIGURE 1.5 β-oxidation of fatty acids ................................................................ 19 
FIGURE 1.6 Inhibition of cholesterol synthesis by policosanol  
and its components............................................................................................. 20 
FIGURE 1.7 Effect of policosanol and triacontanol on  
HMG-CoA reductase activity ............................................................................... 21 
FIGURE 1.8 Effect of policosanol and triacontanol on 
HMG-CoA reductase activity................................................................................22 
FIGURE 4.1 Policosanol activates AMP-kinase in vitro ...................................... 37 
FIGURE 4.2 Policosanol activates HMG-CoA reductase in vitro ........................ 39 
FIGURE 4.3 Single dose-response studies: Policosanol 
increases the phosphorylation of AMP-kinase and 
HMG-CoA reductase (HMGR) in vivo at 25 mg/kg ............................................. 41 
FIGURE 4.4 Single dose-response studies: Policosanol 
increases the phosphorylation of AMP-kinase and HMG-CoA 
reductase in vivo at 50 mg/kg ............................................................................. 42 
FIGURE 4.5 Single dose-response studies: Policosanol 
increases the phosphorylation of AMP-kinase and HMG-CoA 
reductase in vivo at 100 mg/kg ........................................................................... 43 
FIGURE 4.6 Policosanol activates CAMKK but not LKB1…………………...…….45 
FIGURE 4.7 siRNA-mediated suppression of fatty aldehyde 
dehydrogenase 3A2 (ALDH3A2) prevents the increase in 
phosphorylation of AMP-kinase and HMG-CoA 
reductase by policosanol .................................................................................... 49 
FIGURE 4.8 siRNA-mediated suppression of peroxisomal fatty 
 ix 
acyl CoA synthetase-4 (ACSL4) prevents the increase in 
phosphorylation of AMP-kinase and HMG-CoA 
reductase by policosanol .................................................................................... 50 
FIGURE 4.9 siRNA-mediated suppression of acetyl-coenzyme A  
acyltransferase 1 (ACAA1) prevents the increase in  
phosphorylation of HMG-CoA reductase by policosanol ..................................... 51 
FIGURE 4.10 Schematic diagram of policosanol metabolism to 
acetyl-CoA and propionyl-CoA through the fatty alcohol cycle and  
peroxisomal β-oxidation ...................................................................................... 52 
FIGURE 4.11 Treatment of hepatoma cells with sodium acetate 
promotes the phosphorylation of AMP-kinase .................................................... 54 
FIGURE 4.12 Sodium acetate treatment increases the 
phosphorylation of CaMKK but not of LKB1 ....................................................... 57 
FIGURE 4.13 Policosanol does not activate 
AMPK in mouse intestine ................................................................................... 59 
 
 
 
 1 
CHAPTER ONE 
BACKGROUND 
 
Cholesterol has exerted a hypnotic fascination for scientists in the medical field 
and is the most highly decorated small molecule in biology (Brown and Goldstein, 
1986). Cholesterol is a component of lipoprotein complexes in the blood and is 
thought to be one of the major causes of the formation of atherosclerotic plaques 
which lead to heart disease and stroke, the foremost cause of premature death 
in Western societies (Egan and Lackland, 1998; Franklin and, Sanders, 2000; 
American Heart Association, 2001).  But, contrary to popular belief, cholesterol 
has a number of essential physiological functions.  In many neurons, a myelin 
sheath, rich in cholesterol, provides insulation for more efficient conduction of 
impulses.  Cholesterol is an important modulator of membrane fluidity in 
mammalian systems.  It is a major constituent in the plasma membranes of 
animals and smaller quantities are found in the membranes of intracellular 
organelles.  Plants contain no cholesterol but instead contain structurally 
related sterols, including stigmasterol and β-sitosterol.  Within the cell 
membrane, cholesterol functions in intracellular transport, cell signaling and 
nerve conduction.  Cholesterol is essential for the structure and function of 
invaginated caveolae and clathrin-coated pits (Rodal et al., 1999).  
Cholesterol-rich compartmentalized domains (rafts/caveolae) have been 
implicated in a variety of cellular processes, including signal transduction, 
endocytosis, transcytosis and cholesterol trafficking (Barnett-Norris et al., 2005).   
 
Cholesterol is an amphipathic molecule.  It consists of a polar hydroxyl head 
group at C-3 and a nonpolar steroid nucleus and hydrocarbon side chain at C-17.  
The biosynthesis of this 27-carbon compound, though highly complex and 
energy-expensive, is derived from the simple precursor, acetate.  Elucidation of 
this pathway by Konrad Bloch and others in 1950s has lead to our understanding 
of the transport of cholesterol, its receptor-mediated endocytosis, and the means 
by which intracellular cholesterol production is influenced by dietary intake.  
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Cholesterol is a precursor to bile acids (e.g., cholate, glycocholate, taurocholate) 
and a variety of steroid hormones including testosterone (produced in testis), 
estradiol and progesterone (produced in ovaries and placenta), cortisol and 
aldosterone (produced in the cortex of the adrenal gland).  Vitamin D3 derived 
from 7-dehydrocholesterol is the precursor to calcitriol, which regulates calcium 
and phosphate metabolism.  
 
Cholesterol and cholesteryl esters are carried in the blood as plasma 
lipoproteins.  Very low-density lipoprotein (VLDL) carries cholesterol, 
cholesteryl esters, and triacylglycerols from the liver to other tissues, where the 
triacylglycerols are catabolized by lipoprotein lipase, converting VLDL to low 
density lipoprotein (LDL).  The LDL is taken up by receptor-mediated 
endocytosis in the liver via the LDL receptor.  A genetic deficiency of this 
receptor is associated with increased blood levels of LDL and risk of heart attack 
and stroke.  High-density lipoprotein (HDL) serves to remove cholesterol from 
peripheral tissues, carrying it to the liver.  A high level of HDL in the blood is 
associated with a decreased risk of cardiovascular disease; therefore, HDL has 
been dubbed the 'good cholesterol' as opposed to LDL, the 'bad cholesterol'.  
Cholesterol can be obtained from the diet and be synthesized in the liver.  
Dietary cholesterol is transported from the small intestine to the liver by 
chylomicrons.  The homeostatic control mechanisms such as synthesizing new 
cholesterol, excreting cholesterol into the bile, and transforming it into bile acids 
operate to keep plasma cholesterol relatively constant, and all occur in the liver.   
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Figure 1.1: Cholesterol transport in the body 
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Use of natural products to lower cholesterol 
 
A reduced life span is an outcome associated with many prevalent diseases, 
including hypercholesterolemia, diabetes and obesity.  In an effort to prevent 
these diseases, many researchers have looked into the identification of natural 
products and nutritional supplements that have cholesterol-lowering efficacies.  
There is evidence that soy protein, tea extracts, policosanol, guggulipids 
(Davidson and Geohas, 2003) and many other natural products can lower 
cholesterol levels (Chagan et al., 2002).  Clinical trial evidence strongly 
supports the notion that both red yeast rice and black tea theaflavins may lower 
LDL (Becker et al., 2009; Davies et al., 2003).  Also, there is strong clinical trial 
evidence suggesting that marine omega-3 fatty acids lower triglycerides 
(McGowan and Proulx, 2009). 
 
Phytosterols, found in all vegetable foods and an essential part of Mediterranean 
diet, inhibit intestinal cholesterol absorption and have a serum 
cholesterol-lowering effect (Escurriol et al., 2009).  They act by either a) 
attenuating the NPC1L1 gene expression which result in a lower cholesterol 
uptake from the lumen; b) lowering the cholesterol esterification rate by the 
ACAT2 (acyl-CoA cholesterol acyltransferase) and hence the amount of 
cholesterol secreted via the chylomicrons, and c) upregulating the expression of 
ABC-transporters ABCG5 and ABCG8 in intestinal cells, which result in an 
increased excretion of cholesterol by the enterocyte back into the lumen 
(Sanclemente et al., 2009). 
 
Green tea catechins are also currently used as safe and effective lipid-lowering 
therapeutic agents, and reduce the risk of cardiovascular diseases (e.g., 
coronary heart disease) by lowering the plasma levels of cholesterol and 
triglyceride (Koo and Noh, 2007).  Studies in vitro indicate that green tea 
catechins, particularly (−)-epigallocatechin gallate, interfere with the 
emulsification, digestion, and micellar solubilization of lipids, critical steps 
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involved in the intestinal absorption of dietary fat, cholesterol, and other lipids 
(Koo and Noh, 2007). 
Soy protein isoflavones, in addition to lowering plasma cholesterol and 
triglycerides, downregulate hepatic SREBP-1 expression through an 
insulin-independent mechanism (Velasquez and Bhathena, 2007). 
 
Garlic and garlic-derived compounds also lowers blood cholesterol levels 
through inhibition of cholesterol synthesis.  Early studies on the inhibition of 
cholesterol synthesis by garlic indicated that inhibition of HMG-CoA reductase 
was the likely mechanism (Qureshi et al., 1983).  However recently Singh and 
Porter, 2006 reported that diallyl disulfide, diallyl trisulfide, and allyl mercaptan 
present in garlic causes the accumulation of sterol 4α-methyl oxidase substrates  
with radiolabelling studies coupled with  gas chromatography–mass 
spectrometry indicating this enzyme as the principal site of inhibition in the 
cholesterologenic pathway by garlic.  Their conclusion is also in accord with the 
view that 4-dimethylated sterols, including lanosterol and dimethylzymosterol, 
have been shown to promote the degradation of HMG-CoA reductase via an 
Insig-mediated pathway (Song et al., 2005).  Garlic is an also effective inhibitor 
of squalene monooxygenase.  Garlic compounds appear to bind to vicinal 
cysteines on squalene monooxygenase, and this inhibition can be prevented by 
thiols and reversed by dithiols (Gupta and Porter, 2001). 
 
Resveratrol, a polyphenol found in grape skin and red wine, is beneficial in the 
prevention of some cholesterol-mediated diseases including cardiovascular 
disease (Leifert and Abeywardena, 2008).  Pleiotropic effects include inhibition 
of oxidation of LDL, activating novel proteins that prevent cell senescence, e.g. 
Sirtuin 1 (Dohadwala and Vita, 2009), inhibition of specific cholesterol 
uptake/transporters, such as the Niemann-Pick C1-like 1 cholesterol transporter 
(Leifert and Abeywardena, 2008), and also inhibition of squalene 
monooxygenase in the squalene biosynthesis pathway (Laden and Porter, 
2001). 
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Ginkgo biloba extract has been reported to decrease the total cholesterol 
content and inhibits the activity of HMG-CoA reductase and decreases 
cholesterol influx in cultured hepatocytes (Xie et al., 2009). 
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Policosanol lowers blood cholesterol 
Policosanol is a mixture of higher primary aliphatic alcohols obtained from sugar 
cane wax which have potent cholesterol lowering properties comparable to the 
low to medium dose statin therapy (Castaño et al., 2003).  Policosanol is an 
attractive alternative for those patients who are in need of lipid lowering 
treatment but are reluctant to use, or unable to afford, chemically derived drugs.  
Lipid lowering effects of policosanol have been studied in a number of animal 
species including rodents and dogs.  Serum cholesterol levels in pigs are 
significantly decreased by supplementation of the diet with policosanol 
(Cruz-Bustillo et al., 1991).  At doses of 10-20 mg/day policosanol has been 
shown to lower total and LDL cholesterol by almost 30% and increases the level 
of good HDL cholesterol by almost 15%.  The product is well tolerated and does 
not have any adverse effects (Gouni-Berthold and Berthold, 2002).  In both 
short term (~12 weeks) and long term (up to 2 years) randomized 
placebo-controlled studies policosanol lowered LDL cholesterol in 
normocholsterolemic patients by an average of 33% (Gouni-Berthold and 
Berthold, 2002; Varady et al., 2003).  Similar studies in people with 
hypercholesterolemia, hypertension, type 2 diabetes, elderly and post 
menopausal women resulted in LDL cholesterol reductions of 19-31% (Janikula, 
2002).  Policosanol did not significantly alter the triglyceride levels in any of the 
studies.  In contrast to these studies in man, policosanol had no significant 
favorable effect in changing lipid levels in hamsters (Wang et al., 2003).  
Policosanol has shown a cholesterol lowering effect in rabbits and dogs 
(Arruzazabala et al, 1991, 1992, 1994), swine (Cruz-Bustillo et al, 1991) and 
monkeys (Rodriguez-Echenique et al, 1992).  In monkeys there was also a 
significant reduction of spontaneous aortic atherosclerotic lesions in treated 
animals (Rodriguez-Echenique et al, 1994).  However, several recent studies 
have been unable to demonstrate a significant reduction in serum cholesterol 
levels with policosanol treatment, calling into question the efficacy of this 
regimen (Kassis et al., 2009; McGowan and Proulx, 2009).   
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Policosanol decreases cholesterol synthesis 
A decrease in cholesterol synthesis is the principle mechanism by which 
policosanol lowers blood cholesterol as evidenced by several in vitro and in vivo 
studies.  Policosanol administered orally inhibited hepatic cholesterol 
biosynthesis in rats with a 20% decrease in absolute rates of incorporation of 
3H-water into sterols (Menendez et al.,1996).  LDL catabolism seems to be a 
primary mechanism by which policosanol lowers plasma cholesterol, as low 
density lipoprotein (LDL) processing is markedly enhanced initially.  LDL 
binding, internalization and degradation were significantly increased after 
policosanol treatment (Menendez et al., 1994).  Although a sterol-independent 
mechanism is quite possible for increased activity of LDL receptor, studies 
suggest that this is due to inhibition of cholesterol biosynthesis (Menendez et al, 
1994).  Cholesterol biosynthesis is decreased in a dose dependent manner from 
[14C] acetate and 3H water but not from [14C] mevalonate when human fibroblasts 
was incubated with policosanol, suggesting a role for its modulation of HMG-CoA 
reductase activity.  However, no evidence of competitive nor non-competitive 
inhibition of enzyme activity was observed in this study, thus negating it as a 
direct inhibitor of HMG-CoA reductase.  When cells were grown in lipid-depleted 
media policosanol prevented the upregulation of HMG-CoA reductase activity 
(Menéndez et al., 2001a) but mRNA and protein levels were not measured in this 
study, making it difficult to determine if this decrease in reductase activity was 
due to increased degradation or decreased synthesis of the enzyme.  Moreover, 
it remained possible that a metabolite of policosanol directly inhibits enzyme 
activity. 
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Composition and metabolism of policosanol 
Policosanol is a natural mixture of aliphatic primary alcohols isolated from 
sugarcane by hydrolytic cleavage and subsequent purification.  It is designated 
as CH3-(CH2) n-CH2OH.  Analysis of a commercially available 20-mg tablet of 
policosanol after extraction with methylene chloride and subjected to gas 
chromatography/mass spectrometry on an ion trap spectrometer showed the 
peaks for major components as illustrated in Fig 1.2 (Singh et al., 2006).  The 
major components of policosanol are octacosanol (C28, ~60%), triacontanol (C30, 
12-14%), and hexacosanol (C26, 6-12%), while other alcohols (tetracosanol, 
heptacosanol, nonacosanol, dotriacontanol and tetratriacontanol) are minor 
components.  Though the active components are unknown, researchers 
hypothesize that the inhibition of cholesterol synthesis is caused by the higher 
primary aliphatic alcohols and also by the presence of long chain fatty acids and 
chain-shortened metabolites.  Studies with C24:0 and C26:0 acids have shown 
that these very long chain fatty acids are oxidized in peroxisomes, rather than 
mitochondria (Singh et al., 1987).  They confirmed that acetate was the 
oxidation product from C24:0 whereas C26:0 and C26:0 CoA was converted to 
acetyl CoA, presumably obtained through β-oxidation.  However, the study 
could not delineate clearly whether peroxisomes had a specific β-oxidation 
system to oxidize very long chain fatty acids or whether the peroxisomal 
β-oxidation long chain fatty acids system was solely responsible (Singh et al., 
1987).  A study on the biodistribution and metabolism of octacosanol in rats 
found it to be partly oxidized and degradation to fatty acids through β-oxidation 
(Kabir and Kimura, 1993).  D-003, a mixture of very long chain saturated fatty 
acids isolated and purified from sugar cane wax, similarly increased serum HDL 
and significantly decreased serum total cholesterol and LDL in rabbits, and 
induced a dose-dependent inhibition in cholesterol biosynthesis (Menendez et 
al., 2004).  The close similarity in chemical structures and a rapid and greater 
decrease in blood lipids with D-003 also suggested that β-oxidation of 
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policosanols to very long chain fatty acids may be necessary for their 
hypocholesterolemic actions (Menendez et al., 2004; Castano et al., 2005). 
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 Fig. 1.2:  Gas chromatogram of policosanol.  Peaks A, B, C, D, and E were 
analyzed by mass spectrometry and shown to correspond to A, C16 
carboxylic (palmitic) acid; B, C18 carboxylic (stearic) acid; C, C26 alcohol 
(hexacosanol); D, C28 alcohol (octacosanol); and E, C30 alcohol (triacontanol). 
(Taken from Singh et al., 2006.) 
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Regulation of HMG-CoA reductase activity 
HMG-CoA reductase (or 3-hydroxy-3-methyl-glutaryl-CoA reductase or HMGR) 
is an endoplasmic reticulum-bound enzyme that catalyzes the rate-limiting step 
in the mevalonate pathway which produces isoprenoids and, ultimately, 
cholesterol.  HMG-CoA reductase contains eight transmembrane segments 
with the active site located in a long carboxyl-terminal domain in the cytosol 
(Roitelman et al., 1992; Istvan and Deisenhofer, 2000).  It is an important 
enzyme in development and is the major drug target for cholesterol-lowering 
drugs.  HMG-CoA reductase is reported to be present in all tissues, but highest 
expression occurs in the liver where it is subject to feedback regulation by 
cholesterol.  HMG-CoA reductase is regulated at multiple levels viz, 
transcription, translation, degradation, and regulation of catalytic efficiency by 
phosphorylation.  Regulation varies with species, with mice and hamsters 
exhibiting transcriptional control while rats show translational regulation (Ness 
and Chambers, 2000).  Sterols affect both the transcriptional rate and 
translational efficiency, whereas hormones, most notably insulin and glucagon, 
affect both transcription and the phosphorylation state of the enzyme (Peffley 
and Gayen, 2003; Ness and Chambers, 2000). 
 
Transcriptional regulation of HMG-CoA reductase is both interesting and unusual, 
as illustrated by Dr. Michael S. Brown and Dr. Joseph L. Goldstein, who won the 
Nobel Prize in Physiology or Medicine in 1985 for their discoveries concerning 
"the regulation of cholesterol metabolism” (Goldstein and Brown, 1990).  
Transcription of the reductase gene is regulated by the sterol regulatory element 
binding protein (SREBP).  This protein binds to the sterol regulatory element 
(SRE), located on the 5' end of the reductase gene.  When SREBP is inactive, it 
is bound to two other proteins: SCAP (SREBP-cleavage-activating protein) and 
Insig1 in the ER or nuclear membrane.  When cholesterol levels fall, Insig-1 
dissociates from the SREBP-SCAP complex, allowing the complex to migrate to 
the Golgi apparatus, where SREBP is cleaved by S1P and S2P (site-1 and -2 
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protease), two enzymes that are activated by SCAP when cholesterol levels are 
low.  The cleaved SREBP then migrates to the nucleus, where it binds to the 
SRE and transcription of genes like LDL receptor and HMG-CoA reductase is 
enhanced.  If cholesterol levels rise, proteolytic cleavage of SREBP from the 
membrane ceases and any proteins in the nucleus are quickly degraded. 
 
HMG-CoA reductase is also regulated through changes in the mRNA stability 
and translation.  Translational efficiency of the reductase mRNA is significantly 
downregulated by dietary cholesterol as seen with decreased association of 
polysomes and subsequently decreased rate of initiation of protein synthesis 
(Chambers and Ness, 1997).  Addition of oxylanosterols also leads to 
translational regulation of HMG-CoA reductase in Chinese Hamster Ovary cells 
(Leonard et al., 1994).  The susceptibility of the reductase enzyme to the 
ER-associated degradation and proteolysis is increased with high levels of 
cholesterol.  Helices 2-6 of the HMG-CoA reductase transmembrane domain 
sense the higher levels of cholesterol and lead to the surface exposure of 
lysine-248.  The enzyme is then ubiquinated by E3 ligase to undergo proteolytic 
degradation. 
 
Microsomal reductase kinase, like HMG-CoA reductase, exists in active as well 
as inactive forms (Ingebritsen et al., 1978; Gibson and Ingebritsen, 1978) and 
can be regulated by phosphorylation (Beg et al.,1973).  This kinase 
corresponds to AMP-kinase (Zammit and Easom, 1987).  HMG-CoA reductase 
is primarily phosphorylated at Ser-872, close to the C-terminus and thus 
inactivated by the AMP-activated protein kinase, which senses AMP levels in the 
cell (Clarke and Hardie, 1990).  AMP-kinase, unlike HMG-CoA reductase, is 
activated by phosphorylation by one or more upstream kinases at the 
threonine-172 position within the activation loop of the α-subunit.  AMP-kinase 
is activated by cellular stresses (eg. hypoxia, glucose deprivation, ischemia) and 
in response to a variety of hormones including glucagon, leptin and adiponetin 
(Hardie, 2003).  AMP-kinase also inactivates acetyl-CoA carboxylase, the 
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regulatory step in fatty acid synthesis (Beg et al., 1987; Carling et al., 1987).  
The list of other targets for AMP-kinase or downstream processes that are 
affected is extensive, as shown in Fig 1.3 below. 
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Fig 1.3: Known physiological target proteins and pathways regulated by the 
AMP-kinase system (modified and adapted from Hardie et al., 2003). 
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Long chain fatty acids can stimulate the phosphorylation and activation of 
AMP-kinase (Clark et al, 2004; Carling et al., 1987) which may provide a 
possible route by which policosanol could activate AMP-kinase and repress 
cholesterol synthesis: policosanol may be oxidized in the cell to the 
corresponding fatty acid, which then directly, or through further metabolites, 
promotes the phosphorylation of AMP-kinase and subsequently, HMG-CoA 
reductase.  A similar but more rapid onset of effects and a greater decrease in 
blood lipids were obtained with very long chain fatty acids (D-003) which also 
indicates that β-oxidation of policosanols to very long chain fatty acids may be 
necessary for their hypocholesterolemic actions (Menendez et al., 2004; 
Castano et al., 2005). 
 
Very long chain fatty alcohol metabolism 
 
Very long chain fatty acids inhibit cholesterol synthesis in cell culture (Menendez 
et al., 2001a).  Notably, peroxisomal diseases, including X-linked adrenal 
leukodystrophy and Sjögren-Larsson syndrome appear to result from defects in 
fatty alcohol and fatty acid metabolism (Hargrove et al., 2004; Rizzo et al., 2001; 
Rizzo and Craft, 2000).  These diseases lead to a number of neurological and 
immunological disorders.  Recent studies also indicate that very long chain fatty 
acids and cholesterol metabolism intersect at various points, particularly in 
regard to peroxisomal fatty acid oxidation and activation of PPARα 
transcriptional system.  Synthesis of ether-phospholipids, important in lipid 
turnover, and oxidation to very long chain fatty acids are the two major pathways 
for utilization of long-chain alcohols.  Interconversion between very long chain 
fatty alcohols, aldehydes and acids have also been reported (Rizzo et al., 1987).  
However, the dominant route for metabolism of fatty alcohols is oxidation to fatty 
acids followed by β-oxidation, as is evidenced by the accumulation of long chain 
alcohols when fatty aldehyde oxidoreductase is deficient (Hargrove et al., 2004). 
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Fig 1.4: Fatty alcohol cycle and peroxisomal β-oxidation. 
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Mixtures of VLCFA from sugarcane inhibit cholesterol synthesis in fibroblasts 
(Menéndez et al., 2001b) and also inhibit lipoprotein oxidation in vitro 
(Menéndez et al., 2002).  A reciprocal relationship between cholesterol 
accumulation and metabolism of VLCFA may exist as viewed from patients with 
defective peroxisomal activity.  Cholesterol depletion also upregulates VLCFA 
metabolism in cultured human fibroblasts and monocytes from patients with 
X-linked adrenoleukodystrophy (Weinhofer et al., 2002). 
 
Animals, many protists, and some bacteria utilize oxidation of long chain fatty 
acids to acetyl-CoA as a central energy-yielding pathway, driving ATP synthesis.  
In vertebrate animals ketone bodies are formed in the liver whereas in plants the 
acetyl CoA is used as a biosynthetic precursor and secondarily as a fuel.  Fatty 
acid oxidation occurs primarily in the mitochondria but peroxisomes of plants 
and animals also carry out β-oxidation.  Fatty acid β-oxidation involves a 
repeating sequence of four reactions to remove each acetyl-CoA unit from the 
carboxyl end of saturated fatty acyl-CoAS: 1) dehydrogenation of the α- and 
β-carbons by the FAD-linked acyl-CoA dehydrogenases; 2) hydration of the 
resulting trans-∆2 double bond by enoyl-CoA hydratase followed by 3) the 
oxidation of the resulting L- β-hydroxyacyl-CoA by NAD-linked 
β-hydroxyacyl-CoA dehydrogenase, and finally 4) thiolysis by acyl-CoA 
acetyltransferase (thiolase) molecule to form acetyl-CoA and an acyl-CoA 
shortened by two carbon atoms.  Fatty acids having an odd number of carbon 
atoms give rise to acetyl CoA (two carbon atoms) and propionyl CoA (three 
carbon atoms) in the final round of fatty acid degradation. 
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Fig 1.5: β-oxidation of fatty acids 
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Inhibition of cholesterol synthesis in hepatoma cells by policosanol 
Previous work by Singh et al. (2006) confirmed that policosanol at 
physiologically relevant concentrations (<10 µg/ml) was able to inhibit 
cholesterol synthesis in hepatoma cells.  They identified triacontanol, a C30 
alcohol, to be the most active component, although octacosanol is the principal 
component of policosanol.  Policosanol was not toxic to cells even at doses up 
to 50 µg/ml as determined by trypan blue exclusion and lactate dehydrogenase 
assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.6:  Inhibition of cholesterol synthesis by policosanol and its components. 
Cholesterol synthesis from 14C-acetate was determined after 3 h in the presence  
of policosanol or its principal components.  Values represent the mean and 
standard error of 2-5 experiments carried out in duplicate.  Asterisk (*) indicates 
statistical significance with respect to untreated cells as determined by one-way 
ANOVA with Tukey’s post-hoc test.  (Taken from Singh et al., 2006.)  
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Policosanol decreased cholesterol synthesis from [14C] acetate but had no effect 
on cholesterol synthesis from [14C] mevalonate (Singh et al., 2006).  This 
finding was reported earlier by Menendez et al. (2001a), indicating that 
policosanol acts at or above HMG-CoA reductase.  Neither policosanol nor 
triacontanol inhibited HMG-CoA reductase when added to rat liver microsomes, 
indicating that there was no direct inhibition of HMG-CoA reductase by these 
alcohols. 
 
 
 
 
 
Fig 1.7:  Effect of policosanol and triacontanol on HMG-CoA reductase activity.  
HMG-CoA reductase activity was measured in microsomes prepared from rat 
liver to which policosanol or triacontanol was added as indicated.  (Taken from 
Singh et al., 2006.) 
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However, HMG-CoA reductase enzyme activity was decreased by almost 55% 
when hepatoma cells, rather than subcellular preparations, were incubated for 3 
hrs with policosanol or triacontanol.  These results suggest that either 
policosanol is metabolized to an active inhibitor or that it reduces the expression 
of HMG-CoA reductase by decreasing transcription and translation or by 
enhancing the degradation of the enzyme. 
 
 
 
  
Fig 1.8:  Effect of policosanol and triacontanol on HMG-CoA reductase activity.  
HMG-CoA reductase activity was measured in lysates prepared from hepatoma 
cells and incubated with the indicated concentrations of policosanol or 
triacontanol.  (Taken from Singh et al., 2006.) 
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Policosanol and triacontanol did not decrease HMG-CoA reductase protein 
levels over the 3 hr period of the experiment, though there was a marked 
decrease in activity of the enzyme.  As HMG-CoA reductase protein levels were 
not changed by policosanol treatment, the possibility lies that policosanol 
inactivates HMG-CoA reductase by promoting its phosphorylation by one of the 
three protein kinases located upstream in the signaling pathway (Beg et al., 
1987). 
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CHAPTER TWO: EXPERIMENTAL RATIONALE 
 
  
The enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) is the 
third enzyme and the regulatory step in the cholesterol biosynthesis pathway.  
Although the most common means to reduce blood cholesterol levels is to inhibit 
the activity of this enzyme directly, it may also be possible to suppress the 
activity of this enzyme indirectly by promoting its phosphorylation.  Indeed, 
policosanol appears to decrease HMG-CoA reductase activity by activating 
AMP-kinase (Singh et al., 2006), the principal regulatory kinase for HMG-CoA 
reductase (Clarke and Hardie, 1990).  The mechanism by which policosanol 
activates AMP-kinase is the subject of this research, and one question 
addressed is whether policosanol requires metabolism to generate an active 
metabolite.  Notably, D-003, a mixture of very long chain fatty acids, also 
suppresses HMG-CoA reductase activity (Menendez et al., 2001b), raising the 
possibility that the long chain primary alcohols of policosanol undergo oxidation 
to the corresponding fatty acid, and perhaps subsequent peroxisomal 
β-oxidation, to form the active metabolite which activates the AMP-kinase 
pathway.  Hence, the purpose of this study is to confirm that policosanol 
activates AMP-kinase and leads to the phosphorylation and inactivation of 
HMG-CoA reductase, to define the upstream signaling pathway or pathways 
through which policosanol or its active metabolite(s) activates this central 
regulatory kinase, and to determine if policosanol, administered orally by gavage, 
activates these pathways in vivo.    
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Specific Aims 
 
Specific Aim 1: Determine the mechanism by which policosanol promotes the 
phosphorylation (and suppression) of HMG-CoA reductase.  This aim has two 
parts: 1) To identify the upstream kinase(s) that are activated by policosanol and 
lead to AMP-kinase phosphorylation and activation; and 2) to determine if 
policosanol must undergo metabolism via the fatty alcohol cycle and 
peroxisomal -oxidation to activate AMP-kinase.  To determine if upstream 
signaling pathways are involved, the phosphorylation states of different kinases 
known to be upstream of AMP-kinase (CaMKK, LKB1 and PKCδ) will be 
determined.  The possibility that policosanol requires metabolism, including 
peroxisomal -oxidation, will be tested through the use of RNAi to suppress the 
expression of enzymes in the fatty alcohol-peroxisomal β-oxidation pathways.  
If metabolism is required these experiments should allow the identification of the 
metabolite that leads to the activation of AMP-kinase.   
 
Specific Aim 2: Determine if policosanol, administered to mice orally by gavage, 
results in the activation of AMP-kinase and the phosphorylation of HMG-CoA 
reductase in the livers of these animals.  These studies will determine the dose 
necessary for activation and determine if the upstream kinases are the same as 
those identified in the hepatoma cell culture studies of Aim 1.  Lastly, because 
the intestine is a significant source of circulating cholesterol, the effect of orally 
administered policosanol on intestinal AMP-kinase and HMG-CoA reductase 
phosphorylation will be determined.  These in vivo studies will extend and 
confirm the corresponding in vitro studies described in Specific Aim 1 and, if 
successful, will provide support for the use of policosanol for the treatment of 
hypercholesterolemia in man. 
. 
 
 
Copyright © Subhashis Banerjee 2010 
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CHAPTER THREE: MATERIALS AND METHODS 
 
Chemicals 
 
The commercial policosanol preparation Lesstanol60 was obtained from Garuda 
International, Inc. (Lemon Cove, CA).  Dulbecco’s modified media (DMEM), 
penicillin-streptomycin-glutamine (PSG, 100X), fetal bovine serum (FBS), 
lipoprotein-depleted serum, and trypsin were purchased from Invitrogen (GIBCO, 
Carlsbad, CA).  Acadesine (AICAR), 1,1-dimethylbiguanide hydrochloride 
(metformin), ionomycin, sodium acetate, and protease inhibitor cocktail were 
obtained from Sigma.  HALT phosphatase inhibitor and the BCA protein assay 
kit were purchased from Roche Diagnostics and Pierce Biotechnology (Rockford, 
IL, USA) respectively.  McA-RH7777 rat hepatoma cells were obtained from 
American Type Culture Collection (Manassas, VA) and used between passages 
12 and 22. 
 
Policosanol 
 
Chemical components of policosanol: LesstanoL® brand policosanol 
contains naturally-occurring waxy alcohols (fatty alcohols) derived from 
sugarcane wax.  Garuda's LesstanoL® Policosanol 60 (OCTA-60) contains a 
minimum of 97% policosanol of which 65.4% is 1-octacosanol along with other 
higher aliphatic alcohols including 1-hexacosanol (5.6%), 1-triacontanol (16.5%), 
1-tetracosanol (2.2%) and 1-dotriacontanol (5.1%). 
 
Preparation of policosanol:  20 mg of policosanol was dissolved in 10 ml of 
50% ethanol with sonication for 30 min with intermittent vortexing.  The solution 
was aliquoted and stored at -20°C, and added directly to media or buffer upon 
use.   
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Cell culture 
  
McA-RH7777 rat hepatoma cells between passages 12 to 22 were cultured in 
Dulbecco’s Modified Eagle’s Medium (Gibco) supplemented with 10% fetal 
bovine serum and 1x Penicillin–Streptomycin (Invitrogen) in six-well plates at 
37°C under a humidified atmosphere of 5% CO2.  After 48 h, the medium was 
replaced with fresh medium with the addition of policosanol (10-25 µg/ml in 50% 
ethanol) and incubation was continued for 3 h.  Control cells received an equal 
volume of 50% ethanol. 
 
Preparation of lysates: Cells were washed once with phosphate-buffered 
saline (pH 7.4) scraped from the plates, pelleted by low-speed centrifugation and 
lysed by two cycles of freeze-thawing in 0.25 M Tris buffer (pH 7.5) containing 
protease and phosphatase inhibitors at 2× standard concentration (Roche 
Diagnostics).  The lysates were cleared by centrifugation (18,300×g, 10 min, at 
4°C) and the supernatant was stored in aliquots at −80°C. 
 
Animals 
 
Experiments involving the use of animals were performed according to the 
protocols approved by the Institutional Animal Care and Use Committee of the 
University of Kentucky and were in accordance with all policies for the use and 
care of laboratory research animals as stipulated by the NIH.  Female C57BL/6 
mice (~15-17 grams) were used in the studies.  Seven-to-eight week-old 
animals were obtained from Jackson laboratories (Bar Harbor, ME) and 
maintained in a temperature-, humidity-, and light- controlled facility (70-72°F, 
48-52% humidity, 12-hr light/dark cycle) and were allowed free access to water 
and food.  The animals were allowed to adjust for 1 week before beginning 
treatments.  At 12 hours before the experiment, food was withdrawn and mice 
in groups of 5 were gavaged with 150 µl of policosanol in 50% ethanol in doses 
of 25 mg/kg, 50 mg/kg and 100 mg/kg body weight.  Control animals received 
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an equal volume of 50% ethanol only.  At specific time points mice were 
euthanized by CO2 asphyxiation and the liver and intestine promptly removed for 
processing; a portion of each was snap-frozen in liquid nitrogen and stored at 
−80°C until used. 
 
Preparation of tissue homogenates: Liver and intestine homogenates were 
prepared as follows:  Approximately 25 mg of tissue was transferred into 4 
volumes of chilled RIPA homogenization buffer (50 mM Tris-HCl, pH 7.4, 150 
mM NaCl, 1 mM PMSF, 1 mM EDTA, 5 µg/ml aprotinin, 5 µg/ml leupeptin, 1% 
Triton X-100, 1% sodium deoxycholate, and 0.1% SDS) and homogenized using 
a Potter-Elvehjem homogenizer.  Protease and phosphatase inhibitors were 
used at 2× standard concentration (Roche Diagnostics).  The samples were 
then subjected to two cycles of freeze–thawing and then cleared by 
centrifugation (18,300×g, 10 min, 4°C).  The supernatant was stored in aliquots 
at −80°C.  Protein concentration was determined by BCA assay (Pierce 
Biotechnology). 
 
Gel electrophoresis and immunoblotting 
 
Thirty micrograms of protein as a cell lysate or tissue homogenate was 
fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 
8% gels and electroblotted to nitrocellulose.  The membrane was blocked with 
0.05% Tween-20 and 5% defatted milk for 1 h at room temperature and then 
incubated in this same buffer with rabbit antibody to total AMP kinase 
(anti-AMPK α-pan, 1:2000; Upstate USA) or to phosphorylated AMP-kinase 
(anti-phospho-AMPKα, 1:500; Upstate USA) overnight at 4°C with gentle 
shaking.  The immunoblot was developed with a secondary antibody 
conjugated to horseradish peroxidase for 1 h at room temperature and the 
chemiluminescent image (Supersignal West Pico Chemiluminescent Substrate, 
Thermo Scientific) captured by autoradiography on a Kodak Image Station or on 
film.  Band intensity on film was measured with Image J software on the 
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scanned image with background subtraction.  The same procedure was 
followed for detecting phosphorylated HMG-CoA reductase 
(anti-phospho-HMG-CoA reductase, 1:500; Millipore USA) and phosphorylated 
PKCδ/λ (anti-phospho-PKCδ/λ, 1:500; Cell Signaling USA). 
 
 Immunoprecipitation  
 
To determine the level of phosphorylation of the kinases LKB1 and CaMKK, cell 
lysates or tissue homogenates were incubated for 1 h at 4°C with 20 μl of mouse 
monoclonal antibody to phosphoserine/phosphothreonine/phosphotyrosine 
(Abcam).  Antibody conjugates were precipitated with 35 μl of protein A or G 
Plus-Agarose from Calbiochem (EMD Chemicals) for 1 h at 4°C by following an 
Amersham Biosciences immunoprecipitation protocol, as follows.  After 
centrifugation at 12,000×g for 20 sec at 4°C, the immunoprecipitated 
phosphoproteins were released from the agarose beads by boiling in 25 µl of 2X 
gel loading buffer [0.5M Tris-HCl (pH 6.8), 4.4% (w/v) SDS, 20% (v/v) glycerol, 
2% (v/v) 2-mercaptoethanol, and bromophenol blue in distilled/deionized water] 
at 95°C for 4 min.  After removal of beads by centrifugation at 12,000×g for 20 
sec at 4°C, the phosphoproteins were fractionated by SDS-gel electrophoresis 
and electroblotted to nitrocellulose as described above.  Phosphorylated 
protein content was detected and quantified with an antibody to the total LKB1 
(anti-LKB1, 1:1000; Sigma USA) and total CaMKK (anti-CaMKK, 1:1000; BD 
Transduction USA) followed by a secondary antibody conjugated with 
horseradish peroxidase as described above. 
 
 
Plasmid preparation 
 
A. E.coli transformation: 
Two µl of each stock solution of SureSilencingTM shRNA plasmid 
(SABiosciences) were used to transform Max Efficiency DH5αTM competent cells 
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(Invitrogen).  The siRNA sequences contained in these plasmids are shown in 
Table 3.1.  After mixing gently, followed by incubation on ice for 5-30 min, the 
cells were heat-shocked for 30 sec at 42°C without shaking, after which 250 µl of 
Super Optimal broth with Catabolite repression (SOC) medium [2% w/v 
bacto-tryptone, 0.5% w/v bacto-yeast extract, 10mM NaCl, 2.5mM KCl, 20mM 
MgSO4, ddH2O to 1000 mL, 20mM glucose] was added and the cells were 
incubated with shaking at 200 rpm at 37°C for 1 hr in a horizontal shaker 
(Hanahan, 1983).  Ten to 50 µl from each transformation was spread on 
prewarmed LB (Luria-Bertani) plates containing 100 µg/ml ampicillin.  Plates 
were incubated overnight at 37°C. 
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Table 3.1: shRNA plasmid sequences used for silencing genes 
Product Unigen
e 
Gen Bank Symbol Clone 
or Ex# 
Sequence 
KR44274 Rn.911
3 
NM_0317
31 
Aldh3a2 1 TCACTGATGTTGACCC
TAACT 
KR44274 Rn.911
3 
NM_0317
31 
Aldh3a2 2 GCAGCGGTTTGATCA
CATTCT 
KR44274 Rn.911
3 
NM_0317
31 
Aldh3a2 3 GGGAGAGAGTGTTAA
CAAACT 
KR44274 Rn.911
3 
NM_0317
31 
Aldh3a2 4 CTGTATTGCTCCTGAC
TATAT 
KR52689 Rn.878
21 
NM_0536
23 
Acsl4 1 GTAGAAGGATCTTGG
GTTGAT 
KR52689 Rn.878
21 
NM_0536
23 
Acsl4 2 GAAGGTGGTTATACAG
TTCAT 
KR52689 Rn.878
21 
NM_0536
23 
Acsl4 3 GGACACATATATTGGC
TACTT 
KR52689 Rn.878
21 
NM_0536
23 
Acsl4 4 TGACCATGCTGTAGC
CAAGTT 
KR44240 Rn.891
3 
NM_0124
89 
Acaa1 1 ATCTCTGTGGGTAAC
GTACTT 
KR44240 Rn.891
3 
NM_0124
89 
Acaa1 2 ATGGCGCGCATTGCC
CAATTT 
KR44240 Rn.891
3 
NM_0124
89 
Acaa1 3 AAAGCCAGAGACTGC
CTGATT 
KR44240 Rn.891
3 
NM_0124
89 
Acaa1 4 GTGGAACTGCCCTGT
CAAGTA 
Scrambl
ed 
RNAi used as control GGAATCTCATTCGATG
CATAC 
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B. Plasmid purification: 
Approximately 10 colonies were picked from each plate with a sterile loop or 
toothpick and were used to inoculate separate 2.5 ml cultures of LB medium 
containing 100 µg/ml ampicillin, incubated with shaking at 37°C for 6 hrs until just 
a hint of turbidity was observed.  Then these small cultures were used to 
inoculate 250 ml of LB medium containing 100 µg/ml ampicillin and incubated 
overnight.  The cells were then collected and the plasmid DNA was purified 
using the Wizard Plus SV Midiprep DNA Purification System (Promega) for high 
copy number plasmids. 
  
Transfections 
 
The day before transfection, McA-RH7777 hepatoma cells were plated in 6-well 
plates at a density of 8x104 cells per cm2.  Plasmid DNA was transfected into 
cells with use of Fugene 6 transfection reagent (Roche Diagnostics), as follows:  
Plasmid DNA was mixed with Fugene 6 transfection reagent in serum-free 
medium at a ratio of 1 µg:5 µl and complexes were allowed to form for a 
minimum of 30 min at room temperature.  The medium then was replaced with 
antibiotic-free medium with 10% FBS and the transfection mixture was added 
drop-wise to the cells with gentle swirling.  Cells were assayed 24 hr post 
transfection for transfection efficiency (~25-30%) as determined by 
cotransfection of a β-galactosidase expression plasmid. 
 
RT-PCR 
 
A. RNA isolation: Total RNA was isolated from cells with the use of TRIzol 
reagent (Invitrogen) and the concentration of RNA was measured 
spectrophotometrically with the use of a Nanodrop instrument (Thermo 
Scientific). 
B. Reverse transcriptase reaction: First strand cDNA synthesis was 
performed using Superscript ΙΙ Reverse Transcriptase (Invitrogen).  Exactly 200 
 33 
ng of random primers, 5 µg of total RNA, and 1 µl of dNTP mix (10 mM each 
nucleotide) were mixed in a total volume of 12 µl in diethylpyrocarbonate-treated 
water.  The mixture was heated to 65°C for 5 min, quickly chilled on ice and 
then 4 µl of 5x First Strand Buffer, 2 µl of 0.1 M DTT, 1 µl RNaseOUT (Invitrogen) 
and 200 units of Superscript ΙΙ Reverse Transcriptase was added.  The reaction 
was incubated at 25°C for 10 min, followed by 50 min at 42°C and then 
inactivated by incubation at 70°C for 15 min.  Synthesized single-stranded 
cDNA (sscDNA) was quantified by Nanodrop measurement (Thermo Scientific), 
aliquoted and stored at -20°C. 
C. Real-time PCR: Gene-specific primers for real-time polymerase chain 
reaction (PCR) were designed using Primer 3 software 
(http://frodo.wi.mit.edu/primer3/).  The sequences of the primers are shown in 
Table 3.2.  Each 20-µl PCR reaction mixture contained 0.1 µg of single-stranded 
cDNA or template, 0.5 µl of gene-specific primers (10 µM each), 3 µl of dNTP mix 
(200 µM each nucleotide) and 1 x SYBR Green PCR buffer (Applied 
Biosystems).  Cycling conditions were: 2 minutes at 50°C to activate, initial 
denaturation for 10 min at 95°C, followed by 50 cycles of denaturation for 15 sec 
at 95°C and 1 min of annealing/extension at 55°C.  In order to detect nonspecific 
amplification, dissociation curves were established for each PCR product.  The 
detection and quantitation of nucleic acids levels was done by using the 
comparative delta-delta ct method (Livak and Schmittgen, 2001). 
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 Table 3.2: Gene specific primers used in real-time PCR.   
                                                             
Gene            Primers 
β actin Fw: 5’-CCG TGA AAA GAT GAC CCA GAT C -3’ 
Rw: 5’- AAT GCC AGT GGT ACG ACC AGA -3’ 
ALDH3A2 Fw: 5’- GCG AGA GAA GGA CAT CTT GG -3’ 
Rw: 5’- TCG TCC ATC ATG GTA AGC AG -3’ 
ACSL4 Fw: 5’- CAC CAT TGC CAT TTT CTG TG -3’ 
Rw: 5’- ATA ATG CCG CCT TCA GTT TG -3’ 
ACAA1 Fw: 5’- GGT CCA AGG CTG AAG AAC TG -3’ 
Rw: 5’- CAG TAG AGG GCC TGA CTT GC -3’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Subhashis Banerjee 2010 
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CHAPTER FOUR: RESULTS 
 
Phosphorylation of AMP-kinase and HMG-CoA reductase after policosanol 
treatment 
 
Cholesterol synthesis is a highly regulated pathway and is subject to 
transcriptional, translational, and post-translational modulation (Espenshade 
and Hughes, 2007).  Singh et al. (2006) showed that policosanol decreased 
cholesterol synthesis but did not directly inhibit HMG-CoA reductase, and 
incubation of hepatoma cells with policosanol did not affect HMG-CoA reductase 
protein levels.  However, reductase activity was decreased by up to 55% in 
lysates prepared from these cells, suggesting that HMG-CoA reductase activity 
was down-regulated by policosanol treatment and that this was the mechanism 
by which policosanol decreases cholesterol synthesis.  Because HMG-CoA 
reductase protein levels were not changed by policosanol treatment, I 
considered the possibility that policosanol inactivates HMG-CoA reductase by 
promoting its phosphorylation by one of three protein kinases known to 
inactivate HMG-CoA reductase (Beg et al., 1987).  AMP-kinase is the principal 
kinase involved in the phosphorylation-mediated inactivation of HMG-CoA 
reductase (Carling et al, 1989) and is itself activated by phosphorylation by 
upstream kinases (Hardie, 2003; Towler and Hardie, 2007).  To determine if 
policosanol might be down-regulating the activity of HMG-CoA reductase, the 
ability of policosanol to activate AMP kinase by promoting its phosphorylation 
was determined.  Policosanol increased AMP-kinase phosphorylation in 
hepatoma cells by more than 2.5-fold after 3-hr treatment, with maximal 
stimulation occurring at 15-25 μg/ml (Fig 4.1A).  These increases were 
statistically significant and were comparable to the increases seen with AICAR 
and metformin, both of which are known to activate AMP kinase by 
phosphorylation and served as positive controls.  No change in the level of total 
AMP kinase protein levels were observed over the 3-hr period of the experiment, 
despite a marked increase in the activity of this enzyme.  These results are 
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consistent with the in vitro studies of Singh et al. (2006), where it was shown that 
treatment of hepatoma cells with policosanol increased the phosphorylation of 
AMP-kinase and decreased HMG-CoA reductase activity and cholesterol 
synthesis. 
Treatment of cells with policosanol rapidly activated AMP-kinase, with an 
increase in phosphorylation evident at 30 min; phosphorylation peaked at 
1.5-hrs and stayed elevated through 3 hrs (Fig 4.1B).  The activation of 
AMP-kinase by policosanol led to the concomitant phosphorylation of HMG-CoA 
reductase, as shown in Fig 4.2.  Increases in HMG-CoA reductase 
phosphorylation occurred in a dose dependent manner with 10-25 μg/ml of 
policosanol.  Treatment of cells with AICAR or metformin yielded a similar 
increase in phosphorylated HMG-CoA reductase. 
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Fig 4.1:  Policosanol activates AMP-kinase in vitro.  (A)  Phosphorylated 
AMP-kinase in hepatoma cells was measured by immunoquantitation with an 
antibody specific for the phosphorylated protein after a 3-h treatment with 
various concentrations of policosanol.  The AMP-kinase activators AICAR and 
metformin (1 mM each) served as positive controls.  Images were acquired on 
a Kodak MM2000 gel documentation station and analyzed for mean intensity 
above background.  Values represent the mean and standard deviation of 3 
experiments.  Statistical significance was determined by one-way analysis of 
variance with Dunnett’s post-hoc test, p < 0.05.  Representative immunoblots of 
phosphorylated (P) and total (T) AMP-kinase are shown below the graph.  
(B) Enzyme phosphorylation in hepatoma cells at various times after treatment 
with 15 μg/ml of policosanol (boxes) or without policosanol (circles).  Values 
represent the mean and standard deviation of four experiments; closed symbols 
are statistically different from untreated controls. Statistical significance was 
determined by one-way analysis of variance with Dunnett's post hoc text (P<.05).  
(B) Enzyme phosphorylation in hepatoma cells at various times after treatment 
with 15 μg/ml of policosanol (boxes) or without policosanol (circles).  Values 
represent the mean and standard deviation of three experiments; closed 
symbols are statistically different from untreated controls.  Statistical 
significance was determined by one-way analysis of variance with Dunnett's 
post hoc text (P<.05).   
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Fig 4.2:  Policosanol inactivates HMG-CoA reductase in vitro.  Phosphorylated 
HMG-CoA reductase in hepatoma cells was measured by immunoquantitation 
with an antibody specific for the phosphorylated protein after a 3-h treatment 
with various concentrations of policosanol.  AICAR and metformin (1 mM each) 
served as positive controls.  Images were acquired on a Kodak MM2000 gel 
documentation station and analyzed for mean intensity above background.  
Values represent the mean and standard deviation of 3 experiments.  Statistical 
significance was determined by one-way analysis of variance with Dunnett’s 
post-hoc test, p < 0.05.  Representative immunoblots of phosphorylated (P) and 
total (T) HMG-CoA reductase are shown below the graph.   
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Menendez et al. (2005) found that free octacosanol and octacosanoic acid were 
present in the liver and plasma of rats fed policosanol, and that chain-shortened 
saturated (myristic, palmitic and stearic) and unsaturated (oleic, palmitoleic) fatty 
acids were formed after oral dosing of monkeys with policosanol.  Moreover, 
because oral dosing is likely to result in significant hepatic exposure, the 
effective concentration therein is likely to be substantially higher; indeed, Kabir 
and Kimura (1995) reported that radiolabeled octacosanol is found 
predominantly in the liver after oral dosing.  In studies by Menendez et al. 
(1996), oral administration of policosanol to rats decreased hepatic cholesterol 
biosynthesis while HMG-CoA reductase activity remained unchanged, 
suggesting that cholesterol synthesis was not inhibited by a direct action of 
policosanol on this enzyme.  My data with cell culture preparations suggests 
that policosanol may promote the phosphorylation of HMG-CoA reductase by 
activation of AMP-kinase, and so it is reasonable to expect that it will act by the 
same mechanism in vivo.  To confirm this supposition, the expression and 
activity of AMP-kinase and HMG-CoA reductase were assessed in the livers of 
mice gavaged with a single oral dose of policosanol at 10 mg/kg, 25 mg/kg, 50 
mg/kg and 100 mg/kg.  As shown in Figs 4.3, 4.4 and 4.5, policosanol was 
highly effective in promoting the phosphorylation of AMP-kinase as well as 
HMG-CoA reductase.  AMP-kinase and HMG-CoA reductase phosphorylation 
increased by ∼2 fold and ~4 fold respectively at 3 h with 25 mg/kg.  Although at 
the 50 mg/kg dosing no 3-hr time point was taken, at 6 hr phosphorylation of 
both enzymes was increased by 2.5-fold.  At 100 mg/kg dose phosphorylation 
was not increased, and in fact was significantly decreased for AMP-kinase at the 
6-hr time point.  Policosanol had no effect on AMP-kinase phosphorylation at 
10 mg/kg dose (data not shown).  Moreover no change in the total AMP-kinase 
was observed at each of time points and the dosing regimens tested.  
 
 
 
 
 41 
Fig 4.3:  Single dose-response studies: Policosanol increases the 
phosphorylation of AMP-kinase and HMG-CoA reductase (HMGR) in vivo at 25 
mg/kg.  Phosphorylated AMP-kinase and HMG-CoA reductase were measured 
by immunoquantitation with antibodies specific for the phosphorylated proteins 
in mice gavaged with 25 mg/kg of policosanol.  Images were acquired on a 
Kodak MM2000 gel documentation station and analyzed for mean intensity 
above background.  Values represent the mean and standard deviation of 2-3 
experiments; values that are statistically different from untreated controls are 
indicated with asterisks.  Statistical significance was determined by one-way 
analysis of variance with Dunnett’s post-hoc test, p < 0.05. 
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Fig 4.4:  Single dose-response studies: Policosanol increases the 
phosphorylation of AMP-kinase and HMG-CoA reductase in vivo at 50 mg/kg.  
Phosphorylated AMP-kinase and HMG-CoA reductase were measured by 
immunoquantitation with antibodies specific for the phosphorylated proteins in 
mice gavaged with 50 mg/kg of policosanol.  Images were acquired on a Kodak 
MM2000 gel documentation station and analyzed for mean intensity above 
background.  Values represent the mean and standard deviation of 2-3 
experiments; values that are statistically different from untreated controls are 
indicated with asterisks.  Statistical significance was determined by one-way 
analysis of variance with Dunnett’s post-hoc test, p < 0.05. 
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Fig 4.5:  Single dose-response studies: Policosanol fails to increase the 
phosphorylation of AMP-kinase in vivo at 100 mg/kg.  Phosphorylated 
AMP-kinase was measured by immunoquantitation with an antibody specific for 
the phosphorylated protein in mice gavaged with 100 mg/kg of policosanol.  
Images were acquired on a Kodak MM2000 gel documentation station and 
analyzed for mean intensity above background.  Values represent the mean 
and standard deviation of 4 experiments; values that are statistically different 
from untreated controls are indicated with asterisks.  Statistical significance was 
determined by one-way analysis of variance with Dunnett’s post-hoc test, p < 
0.05.  Because no increase in AMP-kinase phosphorylation was observed, 
HMG-CoA reductase phosphorylation was not tested. 
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Activation of pathways upstream of AMP-kinase by policosanol 
AMP-kinase itself is activated by phosphorylation by the upstream kinases LKB1 
and TAK1; the binding of AMP to AMP-kinase makes the enzyme a better 
substrate for these kinases (Hardie, 2003; Towler and Hardie, 2007; Xie et al., 
2009).  In addition, three independent studies reported that CaMKK 
phosphorylates and activates AMP-kinase in vitro.  Two of these studies 
provided evidence that CaMKKβ, rather than CaMKKα, is the predominant 
kinase acting on AMP-kinase.  LKB1 is present in liver and muscle and is 
thought to be the principal activating enzyme for AMP-kinase in these tissues.  
Not surprisingly, LKB1 is also regulated by upstream kinases, most notably 
PKCδ and perhaps also PKA and p90 RSK (Xie et al., 2008).  As my studies 
have demonstrated that policosanol activates AMP-kinase both in cell culture 
and in mice in vivo, the upstream kinase pathways leading to AMP-kinase 
phosphorylation are an attractive route to explore in the effort to identify the 
mechanism by which policosanol activates this kinase.  To identify the 
upstream kinase or kinases through which policosanol was signaling, I tested 
the effect of policosanol on CaMKK phosphorylation in hepatoma cells.  The 
Ca2+ ionophore, ionomycin served as a positive control.  Fig 4.6A shows that 
CaMKKβ phosphorylation was increased by ionomycin and policosanol 
treatment ~ 2-fold and ~2.5 fold, respectively, relative to untreated cells.  In vivo, 
policosanol treatment activated CAMKKβ by ~3.7-fold at 6 h and remained 
elevated till 18 h (Fig 4.6B).  In comparison, when McA-RH7777 cells were 
incubated with policosanol, AICAR (negative control), or metformin (positive 
control) there was no significant increase in the LKB1 phosphorylation relative to 
control (Fig 4.6C).  Similarly, no change in the amount of phosphorylation of 
LKB1 was observed in mice after gavaging with policosanol at 50 mg/kg dose 
(Fig 4.6D).  No changes in the amount of phosphorylated PKCδ/λ were noted 
either in vitro or in vivo with policosanol.  These results indicate that although 
LKB1 is the principal AMP-kinase kinase, policosanol appears to utilize CaMKKβ 
to activate AMP-kinase. 
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Fig 4.6: Policosanol activates CaMKK but not LKB1.  Phosphorylated CaMKKβ 
was measured by immunoquantitation with an antibody specific for the 
phosphorylated protein in (A) hepatoma cells after a 3-h treatment with 
policosanol (15 µg/ml), or (B) in vivo at 6, 12, and 18 h after gastric gavage with 
50 mg/kg body weight policosanol.  Ionomycin served as a positive control in 
(A).  Phosphorylated LKB1 was similarly immunoprecipitated from hepatoma 
cell lysates (C) or mouse liver homogenates (D) with an antibody to 
phosphoserine/phosphothreonine/phosphotyrosine and then quantified by 
immunoblotting with an antibody to total LKB1.  Metformin (1 mM) served as a 
positive control and AICAR (1 mM) as a negative control in (A).  Mice were 
gavaged with 50 mg/kg body weight of policosanol.  Images were acquired on a 
Kodak MM2000 gel documentation station and analyzed for mean intensity 
above background.  Values represent the mean and standard deviation of 2-3 
experiments; values that are statistically different from untreated controls are 
indicated with asterisks.  Statistical significance was determined by one-way 
analysis of variance with Dunnett’s post-hoc test, p < 0.05. 
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Activation of AMP-kinase by policosanol requires peroxisomal metabolism 
Regulation of fatty alcohol metabolism is poorly understood, and there is 
uncertainty as to whether the synthesis and oxidation of fatty alcohols is 
catalyzed by the same enzymes (Riendeau and Meighen, 1985).  Long chain 
fatty alcohols are substrates for the ‘fatty alcohol cycle’ which converts 
long-chain alcohols to their corresponding fatty acids, and reduces long-chain 
fatty acids back to alcohols for incorporation into glycerol-ether lipids (Rizzo et 
al., 1987).  These fatty acids perhaps undergo subsequent peroxisomal 
β-oxidation as was first revealed by the recognition that patients with inherited 
disorders of peroxisomal biogenesis had impaired ether lipid synthesis 
(Heymans et al., 1983; Heymans et al., 1984; Schutgens et al., 1984; Datta et al., 
1984).  Also, defective peroxisomal β-oxidation leads to accumulation of 
very-long-chain fatty acids (Rizzo, 1998).  The fatty alcohol pathway is found on 
both the endoplasmic reticulum and peroxisomal surface (Rizzo, 1998; Hargrove 
et al., 2004).  To determine if the metabolism of long-chain fatty alcohols that 
make up policosanol occurs through the fatty alcohol cycle, and if subsequent 
peroxisomal β-oxidation is necessary for activation of AMP-kinase, I suppressed 
the expression of 1) fatty aldehyde dehydrogenase 3A2 (ALDH3A2), 2) the 
peroxisomal acyl-CoA synthetase long-chain family member 4 (ACSL4), and 3) 
peroxisomal acetyl-coenzyme A acyltransferase 1 (β-ketothiolase, ACAA1) using 
RNA interference (RNAi) to decrease the mRNA levels for these enzymes.  To 
ensure that the RNAi decreased the expression of these enzymes, mRNA levels 
for these enzymes were measured both in treated and scrambled RNAi-treated 
cells at different timepoints (2-10 days) by real-time polymerase chain reaction 
(PCR).  The scrambled RNAi plasmid serves as a negative control for these 
studies.  There was significantly greater than 95% suppression of fatty 
aldehyde dehydrogenase 3A2 expression at 4 and 6 days (Fig 4.7A), greater 
than 95% suppression of peroxisomal acyl-CoA synthetase 4 expression at 2, 4, 
6 and 8 days (Fig. 4.8A), and greater than 80% and 95% suppression of 
peroxisomal acetyl-coenzyme A acyltransferase 1 expression at 4 and 6 days 
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respectively (Fig. 4.9A).  The suppression of these enzymes proved successful 
in preventing the increase in phosphorylation of AMP-kinase and HMG 
CoA-reductase after policosanol treatment.  AMP-kinase phosphorylation was 
significantly decreased at 8 days (relative to the policosanol-treated 6-day 
control) in cells in which ALDH3A2 expression was suppressed (Fig 4.7B), and 
at 4, 6, and 8 days in cells in which ACSL4 expression was suppressed (Fig 
4.8B).  Suppression of ACAA1 yielded non-significant decreases in the 
phosphorylation of AMP-kinase relative to policosanol-treated control cells (Fig 
4.9B).  However, the increase in HMG-CoA reductase phosphorylation after 
policosanol treatment was significantly attenuated in cells in which ALDH3A2 
(Fig 4.7C), ACSL4 (Fig 4.8C), and ACAA1 (Fig 4.9C), expression was 
suppressed.  These results indicate that the production of either acetyl-CoA or 
propionyl-CoA formed after complete β-oxidation of policosanol (Fig 4.10) leads 
to the phosphorylation of HMG-CoA reductase by policosanol.  
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Fig 4.7:  siRNA-mediated suppression of fatty aldehyde dehydrogenase 3A2 
(ALDH3A2) prevents the increase in phosphorylation of AMP-kinase and 
HMG-CoA reductase by policosanol.  Using the four individual shRNA plasmids 
supplied, one plasmid was selected that provided the greatest decrease in 
mRNA levels over a period of 2-10 days using the real-time qRT-PCR procedure 
(data not shown).  Using that selected plasmid and control cells with a 
scrambled RNAi plasmid, AMP-kinase and HMG-CoA reductase 
phosphorylation was measured by immunoquantitation as described earlier after 
incubating the cultures with 15 µg/ml policosanol.  Values represent the mean 
and standard deviation of 2-3 experiments; values that are statistically different 
from untreated controls are indicated with asterisks.  Statistical significance was 
determined by one-way analysis of variance with Tukey’s post-hoc test, p < 0.05. 
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Fig 4.8:  siRNA-mediated suppression of peroxisomal fatty acyl CoA 
synthetase-4 (ACSL4) prevents the increase in phosphorylation of AMP-kinase 
and HMG-CoA reductase by policosanol.  Using the four individual shRNA 
plasmids supplied, one plasmid was selected that provided the greatest 
decrease in mRNA levels over a period of 2-10 days using the real-time 
qRT-PCR procedure (data not shown).  Using that selected plasmid and control 
cells with a scrambled RNAi plasmid, AMP-kinase and HMG-CoA reductase 
phosphorylation was measured by immunoquantitation as described above after 
incubating the cultures with 15 µg/ml policosanol or 1 mM metformin.  Values 
represent the mean and standard deviation of 2 experiments; values that are 
statistically different from untreated controls are indicated with asterisks.  
Statistical significance was determined by one-way analysis of variance with 
Tukey’s post-hoc test, p < 0.05. 
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Fig 4.9:  siRNA-mediated suppression of acetyl-coenzyme A acyltransferase 1 
(ACAA1) prevents the increase in phosphorylation of HMG-CoA reductase by 
policosanol.  Using the four individual shRNA plasmids supplied, one plasmid 
was selected that provided the greatest decrease in mRNA levels over a period 
of 2-10 days using the real-time qRT-PCR procedure (data not shown).  Using 
that selected plasmid and control cells with a scrambled RNAi plasmid, 
AMP-kinase and HMG-CoA reductase phosphorylation was measured by 
immunoquantitation as described earlier after incubating the cultures with 15 
µg/ml policosanol or 1 mM metformin.  Values represent the mean and 
standard deviation of 2 experiments; values that are statistically different from 
untreated controls are indicated with asterisks.  Statistical significance was 
determined by one-way analysis of variance with Tukey’s post-hoc test, p < 0.05. 
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Fig 4.10: Schematic diagram of policosanol metabolism to acetyl-CoA and 
propionyl-CoA through the fatty alcohol cycle and peroxisomal β-oxidation.  The 
enzymes which were suppressed by RNAi in the present experiments are 
indicated. 
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Activation of AMP-kinase by policosanol results from the generation of 
excess acetyl-CoA via peroxisomal metabolism 
Increased short-chain fatty acid production (including acetate) by colonic 
bacterial fermentation of dietary fibers has been reported to have several 
beneficial metabolic effects including lowering of plasma cholesterol (Higgins, 
2004).  It has also been suggested that activation of AMP-kinase in the liver 
might be the principal mechanism for the hypoglycemic effect of acetate 
(Sakakibara et al., 2006).  As the principal product of fatty acid -oxidation is 
acetyl-CoA, it was of interest to see if addition of acetate to cells similarly 
promoted the phosphorylation of AMP-kinase and HMG-CoA reductase.  
Indeed, treatment of hepatoma cells with 10 to 25 µg of sodium acetate for 3 hr 
yielded a statistically significant increase in the phosphorylation of AMP-kinase 
at the 25 µg/ml dose (Fig. 4.11).   
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Fig 4.11: Treatment of hepatoma cells with sodium acetate promotes the 
phosphorylation of AMP-kinase.  Phosphorylated AMP-kinase was measured 
by immunoquantitation with an antibody specific for the phosphorylated enzyme 
in hepatoma cells after a 3-h treatment with the AMP-kinase activators AICAR or 
metformin (1 mM each), policosanol (15 µg/ml) or 10-25 µg/ml sodium acetate.  
Images were acquired on a Kodak MM2000 gel documentation station and 
analyzed for mean intensity above background.  Values represent the mean 
and standard deviation of 3 experiments; values that are statistically different 
from untreated controls are indicated with asterisks.  Statistical significance was 
determined by one-way analysis of variance with Dunnett’s post-hoc test, p < 
0.05 
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This result also is in agreement with several published studies:  Kawaguchi et 
al. (2002) and Sakakibara et al. (2006) reported that acetate treatment of rat 
hepatocytes increased AMP-kinase and acetyl CoA carboxylase activation, the 
latter being a substrate for AMP-kinase.  This increase in AMP-kinase activity 
appeared to result from an increase in AMP content of the hepatocytes 
(Kawaguchi et al., 2002).  The liver is responsible for most of the metabolism of 
acetate in the portal circulation (Mortensen et al., 1996) where acetyl-CoA 
synthase catalyzes the following reaction: 
 
Acetate + ATP        Acetyl -CoA + ppi + AMP. 
 
Zydowo et al. (1993) also reported increased hepatic AMP content in the livers of 
mice after intraperitoneal administration of acetate.  As AMP promotes the 
phosphorylation of AMP-kinase, these studies suggest that acetate activation to 
acetyl-CoA promotes the phosphorylation of AMP-kinase through an increase in 
cellular AMP levels. 
 
In recent years it has been determined that both the tumor-suppressor kinase 
LKB1 (Woods et al., 2003; Hawley et al., 2003; Shaw et al ., 2004) and CaMKK 
(Hurley et al., 2005; Woods et al., 2005; Hawley et al., 2005) are important 
AMPK-kinases, which activate AMP-kinase by directly phosphorylating αThr172.  
As my in vitro and in vivo studies with policosanol have shown that it acts 
through CaMKKβ and not through LKB1, and as acetyl-CoA or propionyl-CoA 
are the metabolites formed from policosanol, I wanted to determine if addition of 
sodium acetate to hepatoma cells would similarly promote the phosphorylation 
of CaMKK but not LKB1.  As shown in Fig 4.12A, there was a more than 2-fold 
increase in the CaMKKβ phosphorylation in hepatoma cells with a low 
concentration (10-15 µg/ml) of sodium acetate.  Although not statistically 
significant, this increase was comparable to the increase seen with ionomycin, a 
positive activator of CaMKK.  However, similar to policosanol, there was a 
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dose-dependent decrease in LKB1 phosphorylation relative to control with 
sodium acetate at similar doses (Fig 4.12B).  Thus, my studies indicate that 
sodium acetate, like policosanol, mediates activation of AMPK via CaMKKβ. 
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Fig 4.12: Sodium acetate treatment increases the phosphorylation of CaMKK 
but not LKB1.  Phosphorylated CaMKKβ was measured by immunoquantitation 
with an antibody specific for the phosphorylated enzyme in hepatoma cells after 
a 3-h treatment with 1 µg/ml ionomycin, 5 µg/ml policosanol, or 10-25 µg/ml 
sodium acetate.  Phosphorylated LKB1 was immunoprecipitated from 
hepatoma cell lysates with an antibody to 
phosphoserine/phosphothreonine/phosphotyrosine after treatment of the cells 
with either AICAR or metformin (1 mM each), 15 µg/ml policosanol, or 10-25 
µg/ml sodium acetate, and then quantified by immunoblotting with an antibody to 
LKB1.  Images were acquired on a Kodak MM2000 gel documentation station 
and analyzed for mean intensity above background.  Values represent the 
mean and standard deviation of 2-3 experiments; values that are statistically 
different from untreated controls are indicated with asterisks.  Statistical 
significance was determined by one-way analysis of variance with Dunnett’s 
post-hoc test, p < 0.05. 
 
 
 
       A                                 B                                                              
 
 
 
 
 
 
 
 
 
 
 
C
on
tr
ol
M
et
fo
rm
in
Io
no
m
yc
in
15
ug
 P
ol
ic
os
an
ol
10
ug
 S
od
iu
m
 a
ce
ta
te
15
ug
 S
od
iu
m
 a
ce
ta
te
25
ug
 S
od
iu
m
 a
ce
ta
te
0
200
400
600
Hepatoma cells
C
a
M
K
K
 p
h
o
s
p
h
o
ry
la
ti
o
n
(r
e
la
ti
v
e
 v
a
lu
e
s
)
C
on
tr
ol
A
ic
ar
M
et
fo
rm
in
P
ol
ic
os
an
ol
10
ug
 s
od
iu
m
 a
ce
ta
te
15
ug
 s
od
iu
m
 a
ce
ta
te
25
ug
 s
od
iu
m
 a
ce
ta
te
0
50
100
150
 *
L
K
B
1
 p
h
o
s
p
h
o
ry
la
ti
o
n
(r
e
la
ti
v
e
 v
a
lu
e
s
)
Hepatoma cells
 58 
Policosanol does not activate AMP-kinase in the small intestine 
As up to 25% of total serum cholesterol is obtained from intestinal synthesis, I 
wanted to determine the effect of oral administration of policosanol on the 
phosphorylation state of AMP-kinase in the small intestine.  As shown in Fig 
4.13, policosanol did not promote the phosphorylation of AMP-kinase in the 
small intestine of mice.  Thus, it appears that policosanol would not affect 
cholesterol synthesis in the intestine through modulation of AMP-kinase.   
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Fig 4.13: Policosanol does not activate AMPK in mouse intestine.  
Phosphorylated AMP-kinase was measured by immunoquantitation-kinase with 
an antibody specific for the phosphorylated enzyme in the proximal intestine of 
mice gavaged with 25 mg/kg or 50 mg/kg of policosanol.  Images were 
acquired on a Kodak MM2000 gel documentation station and analyzed for mean 
intensity above background.  Values represent the mean and standard 
deviation of 3-4 experiments; values that are statistically different from untreated 
controls are indicated with asterisks.  Statistical significance was determined by 
one-way analysis of variance with Dunnett’s post-hoc test, p < 0.05. 
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CHAPTER FIVE: SUMMARY OF RESULTS 
 
Policosanol is a mixture of very long chain alcohols isolated from sugarcane and 
other plant-derived sources that has been reported to decrease serum 
cholesterol in animals and humans.  In a number of short as well as long term 
clinical studies policosanol was successful in lowering LDL cholesterol by 33% in 
normocholesterolemic patients and 24% in hypercholesterolemic patients 
(Gouni-Berthold and Berthold, 2002; Varady et al., 2003).  In these patients 
policosanol also increased HDL cholesterol by an average of 17% without 
affecting triglyceride levels.  However, little scientific evidence of the 
mechanism by which policosanol lowers blood cholesterol is known.  Previous 
studies have reported that policosanol at pharmacological concentrations acted 
at or above HMG-CoA reductase (Singh et al., 2006), the third enzyme and the 
regulatory step in the cholesterol synthesis pathway, to decrease cholesterol 
synthesis.  Further studies demonstrated that policosanol did not act as a direct 
inhibitor of this enzyme and did not affect HMG-CoA reductase enzyme levels 
(Singh et al., 2006).  As reductase activity was decreased by up to 55% without 
a change in enzyme levels, Singh et al. (2006) suggested that HMG-CoA 
reductase was being inactivated by phosphorylation by AMP-kinase.  My 
studies extended and confirmed this hypothesis by showing that policosanol 
increased the amount of phosphorylated AMP-kinase in cells by more than 2.5 to 
3-fold after 3 h of treatment at 15- 25 μg/ml, and concurrently increased the 
phosphorylation of HMG-CoA reductase in a dose dependent manner.  The 
time course of activation was also rapid with policosanol, reaching a peak at 
relatively shorter period of 1.5 hrs. 
 
As several studies in animal models have indicated that oral administration of 
policosanol decreases cholesterol synthesis in vivo (Arruzazabala et al., 1994; 
Rodriguez-Echenique et al., 1994; Menendez et al., 1997), I also tested the 
ability of policosanol, administered by gavage, to activate AMP-kinase in vivo.  
The expression and activity of AMP-kinase and HMG-CoA reductase were 
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assessed in the livers of mice gavaged with a single oral dose of policosanol at 
25 mg/kg, 50 mg/kg and 100 mg/kg.  I observed a robust increase in 
AMP-kinase and HMG-CoA reductase phosphorylation at doses of 25 mg/kg and 
50 mg/kg.  AMP-kinase and HMG-CoA reductase phosphorylation increased by 
∼2 fold and ~4 fold respectively at 3 h with 25 mg/kg.  Although at the 50 mg/kg 
dose no 3-hr time point was taken, at 6 hr phosphorylation of both enzymes was 
increased by 2.5-fold.  At the 100 mg/kg dose phosphorylation was not 
increased, and in fact was statistically decreased for AMP-kinase at the 6-hr time 
point.  No change in the total AMP-kinase was observed at each of time points 
and the dosing regimens tested.  These results demonstrate that policosanol 
acts both in vitro and in vivo to activate AMP-kinase and to inactivate HMG-CoA 
reductase. 
 
I also investigated the mechanism by which policosanol activates AMP-kinase.  
LKB1 and CaMMKβ are two upstream kinases that have been reported to 
activate AMP-kinase.  LKB1 appears to be most important in liver (Towler and 
Hardie, 2007) while CaMKKβ is predominantly expressed in neural tissue, 
although much lower levels are detected in a variety of other tissues including 
the liver (Birnbaum, 2005).  My studies have revealed that policosanol acts 
through CaMKKβ and not through LKB1 to activate AMP-kinase in the liver and 
in hepatoma cells. 
 
It has been reported that D-003, a mixture of very long chain fatty acids, also 
suppresses HMG-CoA reductase activity (Menendez et al., 2001b) and that this 
effect was more robust than that of policosanol and occurred at a much faster 
rate.  This observation suggested that the long chain primary alcohols of 
policosanol must undergo oxidation to the corresponding fatty acid in order to 
activate AMP-kinase; it raised the possibility that peroxisomal -oxidation is also 
required.  My studies show that siRNA-mediated suppression of fatty aldehyde 
dehydrogenase 3A2, fatty acyl CoA synthase 4, and acetyl-coenzyme A 
acyltransferase 1 in cell culture prevented the phosphorylation of AMP-kinase 
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and HMG-CoA reductase, indicating that metabolism of policosanol through the 
fatty alcohol cycle and subsequent peroxisomal β-oxidation is necessary for the 
activation of AMP-kinase.   
 
Although the intestine is also a significant source of circulating cholesterol, my 
studies with policosanol did not reveal any measurable change in the activation 
of AMP-kinase in this tissue.  One possible explanation for this lack of effect is 
that enterocytes may not metabolize policosanol through the fatty alcohol cycle 
and peroxisomal oxidation, as they are responsible for the absorption of lipids 
and their transfer into the bloodstream.  Alternatively, it is possible that 
policosanol is not actually absorbed in the small intestine, but instead is 
metabolized to very short chain fatty acids, including acetate, by colonic bacteria, 
and that these substances are then absorbed in the distal colon, where they 
circulate to the liver to activate hepatic AMP-kinase (Wong et al., 2006).  My 
studies are not able to distinguish between these two possibilities.   
 
As the principal product of fatty acid -oxidation is acetyl-CoA, my studies further 
demonstrated that addition of acetate to cells results in the phosphorylation of 
AMP-kinase and HMG-CoA reductase.  This finding argues that the activation 
of AMP-kinase by policosanol results from the generation of excess acetyl-CoA 
via peroxisomal metabolism.  These findings open new perspectives not just for 
the treatment of hypercholesterolemia, but may open new vistas for the control 
of diabetes and metabolic syndrome by activators of AMP-kinase. 
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 CHAPTER SIX: DISCUSSION 
 
 A sizeable amount of data from various animal studies and human clinical 
studies has suggested that policosanol may be an effective means to lower 
serum cholesterol levels.  Low density lipoprotein (LDL) and total cholesterol 
reductions have been found in both normocholesterolemic and 
hypercholesterolemic patients (Gouni-Berthold and Berthold, 2002; Varady et al., 
2003; Castano et al., 2005) after treatment with 5-20 mg of policosanol in both 
short-term (≤12-week) and long-term (up to 2-year) randomized, 
placebo-controlled, double-blind studies.  However, several recent studies have 
been unable to demonstrate a significant reduction in serum cholesterol levels 
with policosanol treatment, calling into question the efficacy of this regimen 
(Kassis et al., 2009; McGowan and Proulx, 2009).  Although few studies have 
investigated the mechanism underlying the actions of policosanol, it was 
speculated that the mixture is able to inhibit cholesterol synthesis and increase 
LDL clearance (Varady et al., 2003).  In the present studies I show that 
policosanol is able to promote HMG-CoA reductase phosphorylation by 
activation of AMP-kinase.  The increased phosphorylation of AMP-kinase can 
affect HMG-CoA reductase activity either by direct phosphorylation and 
consequent inactivation of the enzyme (Beg et al.,1978), or by an indirect 
down-regulation mediated by transcription factors such as SREBP-1 
(Motoshima et al., 2006), thus suppressing cholesterol synthesis.  In my studies, 
both the in vitro incubation of cultured McA-RH7777 hepatoma cells and the in 
vivo treatment of mice with policosanol stimulated the phosphorylation of both 
HMG-CoA reductase and AMP-kinase.  AMP-kinase also inactivates 
acetyl-CoA carboxylase (Carling et al., 1987) and thus there is coordinate 
down-regulation of cholesterol and fatty acid biosynthesis by this kinase 
pathway. 
Complicated interrelationships exist between the different kinases that activate 
AMP-kinase.  LKB1, PPARγ, PKCδ and CaMKKβ all have been suggested to 
 64 
be involved in the activation of AMP-kinase.  Although LKB1 is considered to be 
the major AMP-kinase, my studies both in vivo as well as in vitro show CaMKKβ 
to be the upstream AMPK-kinase through which policosanol acts.  Consistent 
with my studies, CaMKKβ has also been shown to be required in 
receptor-modulated AMPK phosphorylation stimulated by simvastatin (Kou et al., 
2009), a drug widely prescribed for the prevention and treatment of 
hypercholesterolemia and cardiovascular diseases. 
D-003, a mixture of very long-chain fatty acids, inhibits cholesterol synthesis in 
cultured cells (Menendez et al., 2001b), and has been suggested to be more 
effective than policosanol in lowering blood cholesterol levels (Menendez et al., 
2004).  This greater effectiveness may be due to its greater proportion of fatty 
acids greater than 30 carbons in length; Singh et al. (2006) found that 
triacontanol, a C-30 alcohol, was the most effective component tested of the 
several C-26 to C-30 alcohols in policosanol.  However, as my studies have 
demonstrated, policosanol must undergo oxidation, both through the fatty 
alcohol cycle (Rizzo et al., 1987) and via peroxisomal -oxidation, to activate 
AMP-kinase.  Thus, D-003, as a very long chain fatty acid mixture, may be 
more efficacious simply because it bypasses the fatty alcohol cycle and can 
directly enter the peroxisomal oxidation pathway.  Because D-003 also 
suppresses HMG-CoA reductase activity (Menendez et al., 2001b), prior to my 
studies it was unclear if the very long chain alcohols in policosanol must first 
undergo oxidative metabolism via the fatty alcohol cycle to the corresponding 
fatty acids in order to be effective.  It was also not known if subsequent 
peroxisomal β-oxidation occurred, and was required for the activation of 
AMP-kinase.  Pharmacokinetic studies on octacosanol metabolism indicated 
that this very long-chain alcohol can undergo oxidation to CO2 in vivo, 
presumably via these pathways (Kabir and Kimura, 1993).  In the present study, 
siRNA-mediated suppression of several of the enzymes in these oxidative 
pathways was used to determine if the metabolism of the long-chain alcohols in 
policosanol via these pathways is required for the activation of AMP-kinase.  
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Using these siRNA-generating plasmids, selective suppression of the 
expression of three key enzymes, viz, fatty aldehyde dehydrogenase, fatty acyl 
CoA synthase 4, and acetyl-coenzyme A acyltransferase 1 (β-ketothiolase) in 
the fatty alcohol and β-oxidation pathways was carried out, and it was shown 
that both the fatty alcohol pathway and peroxisomal -oxidation is required for 
the activation of AMP-kinase by policosanol.  As it has been known for some 
time that very long chain fatty acids (VLCFA) inhibit cholesterol synthesis in cell 
culture (Murthy et al., 1988; Menendez et al., 2001a; Garcia-Pelayo et al., 2003), 
it is likely that peroxisomal oxidation is also the mechanism by which these lipids, 
as well as D-003, inhibit cholesterol synthesis. 
 
Recently it was reported that acetic acid, when fed via a stomach tube, activates 
hepatic AMP-kinase and reduces hyperglycemia in diabetic mice (Sakakibara et 
al., 2006), and that it also improves insulin sensitivity in subjects with insulin 
resistance or type II diabetes (Johnston et al., 2004).  My studies, in which 
cultured hepatoma cells were treated with acetate, also found increased 
phosphorylation of AMP-kinase.  This finding, in conjunction with acetate 
feeding studies, suggests that acetate, generated from -oxidation of the very 
long chain fatty acids formed from policosanol, is ultimately responsible for the 
activation of AMP-kinase.  In vivo, all acetate taken up from the portal 
circulation is activated by the liver (Mortensen et al., 1996) to acetyl-CoA in a 
reaction that requires ATP.  This may lead to depletion of ATP with the 
concomitant generation of AMP, an allosteric activator of AMP-kinase, when 
acetate is abundant in the portal bloodstream.  Thus, the increased 
AMP-kinase activity in cells treated with acetate might be promoted by the 
increased AMP generated by acetate activation.  Finally, Sakakibara et al. 
(2006) reported that sodium acetate directly activated AMP-kinase and lowered 
the expression of genes including sterol regulatory element binding protein-1 in 
rat hepatocytes, which might explain indirect downregulation of HMG-CoA 
reductase.   
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It is of interest that acetyl-CoA, produced through the β-oxidation of policosanol, 
is the required substrate for cholesterol biosynthesis, and thus an abundance of 
this substrate might be expected to increase cholesterol synthesis.  A possible 
explanation for inhibition in cholesterol synthesis in the face of this substrate 
surplus could be that the phosphorylation of HMG-CoA reductase at Ser 872 by 
AMP-kinase causes a conformational change in the three dimensional shape of 
the enzyme that reduces the Vmax but not the Km of the reductase.  In this 
sense, this conformational change resembles the effect of a reversible 
noncompetitive inhibitor.  Noncompetitive inhibitors cannot be overcome even 
at high substrate concentrations (Lehninger et al., 2008). 
 
Acetyl-CoA carboxylase (ACC) catalyzes the synthesis of malonyl-CoA, the first 
and committed step in fatty acid synthesis.  ACC activity is also suppressed, 
like HMG-CoA reductase, by reversible phosphorylation by AMP-kinase.  
Phosphorylation on the  subunit (ACC-) decreases the synthesis of fatty acids, 
while phosphorylation on the  subunit (ACC-) leads to a decrease in 
malonyl-CoA levels and, moreover, a disinhibition of fatty acid oxidation (Munday 
and Hemingway, 1999).  As my studies suggest that policosanol administration 
may lead to increased -oxidation of fatty acids, it is reasonable to assume that 
concurrent fatty acid synthesis would represent a futile cycle for the cell.  Thus, 
the activation of AMP-kinase, leading to the suppression of the regulatory 
enzyme in fatty acid synthesis, makes sense, as it would suppress fatty acid 
synthesis when fatty acids are abundant and available for oxidation.  Similar to 
the effect of fibrates, the partitioning of fatty acids towards oxidation and away 
from esterification might be an important aspect of the lipid-lowering effects of 
policosanol. 
 
As policosanol gavage did not affect AMP-kinase activation or HMG-CoA 
reductase phosphorylation in the small intestine, it leaves some unanswered 
questions:  Is policosanol absorbed in the small intestine?  Is the small 
intestine resistant to activation of AMP-kinase by this substance?  Alternatively, 
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it is possible that policosanol is being metabolized to short chain fatty acids, 
including acetate, in the distal colon by the colonic bacteria, and these 
short-chain fatty acids are then absorbed and subsequently taken up by the liver 
(Wong et al., 2006). 
 
The observation that policosanol activates AMP-kinase is reminiscent of the 
mechanism of metformin, a drug widely used to treat type II diabetes.  
Metformin not only reduces hyperglycemia but also improves insulin sensitivity 
and modestly lowers blood lipid levels (Zhou et al., 2001).  Metformin acts 
through AMP-kinase to reduce insulin resistance, hyperinsulinemia and obesity 
(Zhou et al., 2001) and in many cases the actions of metformin can be mimicked 
by the AMP-kinase activator AICAR.  However, metformin, unlike policosanol, 
acts through LKB1 to activate AMP-kinase (Shaw et al., 2005). 
 
The suppression of HMG-CoA reductase, besides affecting cholesterol 
biosynthesis, could influence a variety of other physiological pathways, including 
cell cycle progression, as a consequence of the decreased synthesis of 
nonsterol mevalonate derivatives viz, farnesyl, geranyl and geranyl-geranyl 
intermediates.  These isoprenoids are necessary for prenylation of Ras and 
Rho proteins involved in cell signaling that control cell proliferation.  The 
present studies could help us discover the role that policosanol might play in 
regulating metabolic diseases like type II diabetes through pharmacological 
regulation of AMP-kinase.  
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